Walter Smith for ForbesRoche, the Swiss drug giant, will buy New York-based Flatiron Health, which has become a leader in applying big data approaches to medicine, for $1.9 billion. Roche already owned a 12% stake in Flatiron; in total the deal values Flatiron at $2.1 billion. "For us, for Flatiron, it means we're going to accelerate the mission," says Turner. Roche bought Ignyta, a maker of targeted cancer drugs, for $1.7 billion late last year. The drug giant seems to be looking at data as the next big thing as it defends its dominance in oncology.

Source: Forbes February 15, 2018 20:48 UTC